In a double blind, cross-over study we analyzed the effect of ibopamine, an oral dopaminergic agonist, on cardiac rhythm in comparison with placebo. In basal period, we performed clinical history, physical examination, exercise testing, 48 hours of ambulatory ECG monitoring, and rest isotopic ventriculography. At the beginning of each treatment period we evaluated the arrhythmic response with the acute drug testing. After each period of treatment we performed 48 hours of ambulatory ECG monitoring and effort test. The results were compared with the basal period. We prospectively studied 12 men (mean age 54.8 ± 12.19) with congestive heart failure NYHA class II (6 patients) or III (6 patients). Eleven patients had old myocardial infarction and 1 dilated cardiomyopathy. The mean ejection fraction was 36.1 ± 6.6%. Statistical analysis shows no significant difference in the number and complexity of ventricular arrhythmias between ibopamine and placebo neither in the acute drug test [isolated premature ventricular complexes (PVC): basal, 1,295 in ibopamine group and 2,594 in the placebo group; after drug administration, 1,756 and 2,871 respectively) (p = ns) nor in 48 hours of ambulatory ECG monitoring (103,410 isolated PVC in basal study). After drug administration: 121,069 in placebo group vs. 106,992 in ibopamine group) (p = ns). The individual patients' evolution showed no signs of arrhythmogenic effect, neither with ibopamine nor placebo. No side effects were observed. Thus in this study, no arrhythmogenic effect of ibopamine has been observed in patients with congestive heart failure NYHA class II or III.
|Journal||Revista Latina de Cardiologia - Euroamericana|
|Publication status||Published - 29 Mar 1994|
- acute drug testing
- cardiac rhythm
- dopaminergic drugs
- heart failure
- ventricular arrhythmias